They sure make a real nice headline in their earnings report, but when you dig in, I agree. Bladder cancer test kit sales: $154k this quarter vs $128k in the YEAR AGO quarter. In other words, no real change in sales even one year later!! What's happening here??
for a major increase in NMP22 sales just yet but I could be wrong. At least not the quantum increase that we should see when Timm Medical and Diagnostic Products come on line.
I believe but I could be wrong, that the product is not yet available for these partnersto sell. Diagnostic Products is reportedly advertising that NMP22 is soon to be available on its Emmulite tools, but I have not heard that it is in place yet.
Likewise, I believe the schedule for Timm Medical to get its point of sale product is late this year to early next year. But I believe it still needs to be approved by the FDA.
I think Matritech's best hope for increased sales is the greater visibility of the product in Urology circles by virtue of the length of time the product has been on the market and the fact that it has been reported to be a very important tool for detection of bladder cancer by the Journal of Urology and possibly other scientific publications.
We will know more tomorrow and we will just have to wait. My greatest hope is that we will hear that very good progress is being made in the clinical study for NMP66 and that good progress is being made in getting the point of sale NMP22 product ready for market as well as the possibility that Diagnostic Products is near completion in getting NMP22 on its Immulite machinery.
If good progress is being made in these areas, we should have a Very Merry Christmas and 2002 should be a very prosperous year indeed! This time frame is relatively short now.
All IMO! Best wishes longs! Insert standard disclosure here.